Recurrent or Metastatic Nasopharyngeal Carcinoma Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.446 enrolled1 locationNCT06976190
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.202 enrolled20 locationsNCT07258979
Recruiting
Phase 2

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen208 enrolled6 locationsNCT07070479
Recruiting
Phase 2

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen32 enrolled1 locationNCT06472713
Recruiting
Phase 2

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University56 enrolled1 locationNCT06657690
Recruiting
Phase 2Phase 3

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University300 enrolled1 locationNCT06241599